Ziyuanyuan Holdings Group (8223) Fair Value & Analysis
Healthcare · HK · Market cap HK$117M
Fair value as of: Aug 13, 2026
From 6 valuation models · updated 3 days ago
Share price −32.3% over the past month.
Below-average quality, and screening another 60% overvalued on our models.
What matters now
- The model range is unusually wide (HK$0.0500 to HK$0.2100). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$0.1500 – HK$2.78 · fair‑value band HK$0.0500 – HK$0.2100 · the HK$0.1510 price screens above the HK$0.0600 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Ziyuanyuan Holdings Group (8223) currently trades at HK$0.1510, while our model-based Fair Value estimate is HK$0.0600, implying the stock looks roughly 60.3% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Ziyuanyuan Holdings Group generated revenue of HK$482M at a net margin of -2.2%. Revenue declined 13.7% year over year. It earns a return on equity of -3.6%. Net debt stands at HK$228M. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.0500 (bear case) to HK$0.2100 (bull case); at HK$0.1510, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at -7% fair-value upside, at -60%, 8223 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 6 models by family
Widest divergence: Multiples (HK$0.3900) versus Earnings-Based (HK$0.1900). Highest evidence: ROIC Compounder (72).
Notify me when 8223 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 47 · Market factors (momentum, volatility) 15
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Ziyuanyuan Holdings Group Limited, an investment holding company, provides medical equipment finance leasing services in the People's Republic of China. The company operates through Finance Leasing Service, Postpartum Care Service, Trading Business, and Other segments. It offers direct finance leasing and sale-leaseback services.
Full company description
Ziyuanyuan Holdings Group Limited, an investment holding company, provides medical equipment finance leasing services in the People's Republic of China. The company operates through Finance Leasing Service, Postpartum Care Service, Trading Business, and Other segments. It offers direct finance leasing and sale-leaseback services. The company also provides maternal and child postpartum care services; IT services; and technological services. In addition, it trades in medical equipment and consumables, such as dental, maternal and child, and large hospital medical equipment, as well as aesthetic medicine. The company was founded in 2014 and is based in Shenzhen, the People's Republic of China. Ziyuanyuan Holdings Group Limited is a subsidiary of Hero Global Limited.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Ziyuanyuan Holdings Group reported revenue of HK$503M in FY2025 versus HK$119M in FY2021, a compound +43.3%/yr. Reported net income was −HK$10.4M in FY2025.
8223 screens 60% overvalued. Compare with McKesson Corporation →
Peer Group
Medical Distribution · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $878.73 | $819.31 | -7% |
| Cencora, Inc COR | $314.17 | $211.07 | -33% |
| Cardinal Health, Inc CAH | $234.16 | $141.77 | -39% |
| Henry Schein, Inc HSIC | $90.74 | $71.70 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.56 | ¥33.96 | +105% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Galenica AG GALE | CHF 80.85 | CHF 61.79 | -24% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.49 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 80.00 | kr 28.26 | -65% |
Compare Ziyuanyuan Holdings Group with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Ziyuanyuan Holdings Group (8223) overvalued or undervalued?
What is the fair value of 8223?
What is the quality score of 8223?
What is the revenue of Ziyuanyuan Holdings Group (8223)?
What is the net profit margin of 8223?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Ziyuanyuan Holdings Group and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.